Read by QxMD icon Read

memantine rct

Kelvin K F Tsoi, Joyce Y C Chan, Nelson W Y Leung, Hoyee W Hirai, Samuel Y S Wong, Timothy C Y Kwok
BACKGROUND: Acetylcholinesterase inhibitor (AChEI) and memantine are recognized drug treatments with limited clinical efficacy. Combination therapy for patients with Alzheimer disease (AD) was suggested, but the additional benefit of combination therapy is still controversial. AIM: To evaluate the additional benefit of combination therapy over monotherapy with either AChEI or memantine. METHODS: Prospective randomized controlled trials were searched from the OVID databases...
September 1, 2016: Journal of the American Medical Directors Association
F Beisse, R Diem
BACKGROUND: To date, high-dose corticosteroids constitute the only established treatment of acute optic neuritis (ON); however, steroids cannot prevent the loss of retinal nerve fibers. New acute therapeutic drugs are therefore being sought for a reduction of ganglion cell death. METHODS: Literature search comprising clinical studies on treatment of ON with immunomodulatory and neuroprotective drugs. RESULTS: For the immunomodulatory drug simvastatin some evidence for long-term benefits was shown, particularly regarding visual evoked potentials...
May 2016: Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
Nicola Veronese, Marco Solmi, Claudio Luchini, Ru-Band Lu, Brendon Stubbs, Leonardo Zaninotto, Christoph U Correll
BACKGROUND: Acetylcholinesterase inhibitors (AceI) and memantine might prove useful in bipolar disorder (BD) given their neuroprotective and pro-cognitive effects, as highlighted by several case reports. We aimed to systematically review the efficacy and safety of AceI and memantine across multiple outcome dimensions in BD. METHODS: Systematic PubMed and SCOPUS search until 04/17/2015 without language restrictions. Included were randomized controlled trials (RCTs), open label studies and case series of AceI or memantine in BD patients reporting quantitative data on depression, mania, psychotic symptoms, global functioning, or cognitive performance...
June 2016: Journal of Affective Disorders
Jin-Chen Yang, Annette Rodriguez, Ashley Royston, Yu-Qiong Niu, Merve Avar, Ryan Brill, Christa Simon, Jim Grigsby, Randi J Hagerman, John M Olichney
Progressive cognitive deficits are common in patients with fragile X-associated tremor/ataxia syndrome (FXTAS), with no targeted treatment yet established. In this substudy of the first randomized controlled trial for FXTAS, we examined the effects of NMDA antagonist memantine on attention and working memory. Data were analyzed for patients (24 in each arm) who completed both the primary memantine trial and two EEG recordings (at baseline and follow-up) using an auditory "oddball" task. Results demonstrated significantly improved attention/working memory performance after one year only for the memantine group...
2016: Scientific Reports
Taro Kishi, Shinji Matsunaga, Nakao Iwata
BACKGROUND: There is no conclusive evidence supporting the efficacy of memantine in frontotemporal dementia (FTD). We conducted a comprehensive meta-analysis of memantine concerning the efficacy and tolerability of memantine in FTD. METHODS: Studies were identified through searches of PubMed, databases of the Cochrane Library, and PsycINFO citations up to April 10, 2015. Outcomes were Clinical Global Impression (primary), Mini-Mental State Examination, Neuropsychiatric Inventory, and Zarit Burden Interview scores as well as all-cause discontinuation...
2015: Neuropsychiatric Disease and Treatment
Rezvan Noruzzadeh, Amirhossein Modabbernia, Vajiheh Aghamollaii, Majid Ghaffarpour, Mohammad Hossein Harirchian, Sarvenaz Salahi, Nikta Nikbakht, Nahid Noruzi, Abbas Tafakhori
BACKGROUND: Uncontrolled studies in human have suggested that memantine might be a suitable option for migraine prophylaxis. OBJECTIVE: To assess the efficacy and tolerability of memantine for migraine prophylaxis. METHODS: This was a 12-week randomized double-blind placebo-controlled parallel-group study. Sixty patients with migraine without aura were randomized using a computer-generated list to receive memantine (10 mg/day) or placebo for 12 weeks...
January 2016: Headache
Gregory H Pelton, Oliver L Harper, Steven P Roose, Karen Marder, Kristina D'Antonio, D P Devanand
OBJECTIVE: The objective of the study is to assess combined antidepressant and memantine treatment in older patients presenting with depression and cognitive impairment. METHODS: Thirty-five depressed patients with cognitive impairment participated in this open-label pilot study. We evaluated whether, over a 48-week period, combined antidepressant (primarily es-citalopram) and memantine treatment was effective in the treatment of cognitive impairment and depression...
June 2016: International Journal of Geriatric Psychiatry
Narges Shams Alizadeh, Azad Maroufi, Mehnoosh Jamshidi, Kambiz Hassanzadeh, Fardin Gharibi, Ebrahim Ghaderi
OBJECTIVES: Various strategies such as adding cholinesterase inhibitors are used to reduce cognitive impairments during electroconvulsive therapy. In this study, we aimed to assess the effectiveness and safety of memantine as an N-methyl-D-aspartate receptor antagonist in the prevention of cognitive deficits due to ECT. METHODS: Thirty-eight adult patients with various mental disorders were randomized to memantine (10 mg/day initially and 20 mg/day at the end of the first week) or placebo during the ECT period...
November 2015: Clinical Neuropharmacology
Gerardo Gonzalez, Gregory DiGirolamo, Mauricio Romero-Gonzalez, David Smelson, Douglas Ziedonis, Monika Kolodziej
BACKGROUND: Opioid use disorders are considered a serious public health problem among young adults. Current treatment is limited to long-term opioid substitution therapy, with high relapse rates after discontinuation. This study evaluated the co-administration of memantine to brief buprenorphine pharmacotherapy as a treatment alternative. METHODS: 13-week double-blind placebo-controlled trial evaluating 80 young adult opioid dependent participants treated with buprenorphine/naloxone 16-4mg/day and randomized to memantine (15mg or 30mg) or placebo...
November 1, 2015: Drug and Alcohol Dependence
Kelvin K F Tsoi, Hoyee W Hirai, Joyce Y C Chan, Timothy C Y Kwok
BACKGROUND: Alzheimer disease (AD) is a global health problem which afflicts millions of old age population worldwide. Acetylcholinesterase inhibitors and memantine are recognized drug treatments with limited clinical efficacy. It is uncertain if earlier initiation of these drugs will result in better outcomes in the longer term. AIM: To evaluate the benefit of early treatment among people with AD. METHODS: Prospective randomized controlled trials were systematically searched from the OVID databases...
January 2016: Journal of the American Medical Directors Association
K Wictorin, H Widner
OBJECTIVES: The partial glutamate antagonist amantadine is currently used in clinical practice, to reduce dyskinesia developing as a side-effect of levodopa treatment in patients suffering from Parkinson's disease (PD). This study was aimed at evaluating the antidyskinetic effect of another glutamate antagonist, memantine. METHODS AND MATERIALS: We performed a randomized, double-blind and placebo-controlled crossover clinical trial of memantine (20 mg), with a 3-week treatment period, and 15 patients completed the study...
May 2016: Acta Neurologica Scandinavica
William James Deardorff, Eliahu Feen, George T Grossberg
Current pharmacological therapy for Alzheimer's disease (AD) includes the cholinesterase inhibitors (ChEIs) donepezil, rivastigmine, and galantamine and the N-methyl D-aspartate receptor antagonist memantine. Based on the results of randomized controlled trials and several meta-analyses, ChEIs appear to show modest but statistically significant improvements on several measures, including cognition and global functioning. Given their modest effects, there is a lack of consensus among clinicians regarding issues related to initiation, optimal duration, and discontinuation of ChEI therapy across the spectrum of AD...
July 2015: Drugs & Aging
Mohammad Abbasinazari, Ladan Adib-Eshgh, Azin Rostami, Narges Beyraghi, Shideh Dabir, Reyhaneh Jafari
The purpose of this study was to evaluate the effect of memantine administration on the adverse cognitive effects of electroconvulsive therapy (ECT). Forty patients diagnosed with a major depressive disorder for which ECT was indicated as a treatment for their current episode were randomly allocated to either the memantine (5mg/day) group or the placebo group. All patients underwent the same protocol for anaesthesia and ECT procedures. The patients received memantine or the placebo for the whole period of ECT treatment, starting the day before ECT and continuing until the fourth session of ECT...
June 2015: Asian Journal of Psychiatry
Sheng-Yu Lee, Shiou-Lan Chen, Yun-Hsuan Chang, Po See Chen, San-Yuan Huang, Nian-Sheng Tzeng, Liang-Jen Wang, I Hui Lee, Tzu-Yun Wang, Kao Chin Chen, Yen Kuang Yang, Jau-Shyong Hong, Ru-Band Lu
Low-dose memantine might have anti-inflammatory and neurotrophic effects mechanistically remote from an NMDA receptor. We investigated whether add-on memantine reduced cytokine levels and benefitted patients with opioid dependence undergoing methadone maintenance therapy (MMT) in a randomized, double-blind, controlled 12-week study. Patients were randomly assigned to a group: Memantine (5 mg/day) (n = 53) or Placebo (n = 75). The methadone dose required and retention in treatment were monitored. Plasma tumor necrosis factor (TNF)-α, C-reactive protein (CRP), interleukin (IL)-6, IL-8, transforming growth factor (TGF)-β1, and brain-derived neurotrophic factor (BDNF) levels were examined during weeks 0, 1, 4, 8, and 12...
2015: Scientific Reports
Jacob S Buckley, Shelley R Salpeter
BACKGROUND: There is no cure for dementia, and no treatments exist to halt or reverse the course of the disease. Treatments are aimed at improving cognitive and functional outcomes. OBJECTIVE: Our objective was to review the basis of pharmacological treatments for dementia and to summarize the benefits and risks of dementia treatments. METHODS: We performed a systematic literature search of MEDLINE through November 2014, for English-language trials and observational studies on treatment of dementia and mild cognitive impairment...
June 2015: Drugs & Aging
Miguel A Barbancho, Marcelo L Berthier, Patricia Navas-Sánchez, Guadalupe Dávila, Cristina Green-Heredia, José M García-Alberca, Rafael Ruiz-Cruces, Manuel V López-González, Marc S Dawid-Milner, Friedemann Pulvermüller, J Pablo Lara
Changes in ERP (P100 and N400) and root mean square (RMS) were obtained during a silent reading task in 28 patients with chronic post-stroke aphasia in a randomized, double-blind, placebo-controlled trial of both memantine and constraint-induced aphasia therapy (CIAT). Participants received memantine/placebo alone (weeks 0-16), followed by drug treatment combined with CIAT (weeks 16-18), and then memantine/placebo alone (weeks 18-20). ERP/RMS values (week 16) decreased more in the memantine group than in the placebo group...
June 2015: Brain and Language
Jue Jiang, Hong Jiang
The role of memantine as a treatment for Alzheimer's disease (AD) has been controversial. In clinical trials, a high dropout rate and numerous adverse events associated with memantine have been observed. However, given the relative scarcity of effective treatments for AD it would seem prudent to re-examine existing evidence to determine whether or not memantine should be used. Eight databases were utilized for randomized controlled trials that were published prior to December 31, 2013 and were according with the inclusion criteria...
September 2015: Neurological Sciences
Shinji Matsunaga, Taro Kishi, Nakao Iwata
BACKGROUND: We performed an updated meta-analysis of randomized placebo-controlled trials testing memantine monotherapy for patients with Alzheimer's disease (AD). METHODS: The meta-analysis included randomized controlled trials of memantine monotherapy for AD, omitting those in which patients were also administered a cholinesterase inhibitor. Cognitive function, activities of daily living, behavioral disturbances, global function, stage of dementia, drug discontinuation rate, and individual side effects were compared between memantine monotherapy and placebo groups...
2015: PloS One
R Schmidt, E Hofer, F H Bouwman, K Buerger, C Cordonnier, T Fladby, D Galimberti, J Georges, M T Heneka, J Hort, J Laczó, J L Molinuevo, J T O'Brien, D Religa, P Scheltens, J M Schott, S Sorbi
BACKGROUND AND PURPOSE: Previous studies have indicated clinical benefits of a combination of cholinesterase inhibitors (ChEI) and memantine over ChEI monotherapy in Alzheimer's disease (AD). Our objective was the development of guidelines on the question of whether combined ChEI/memantine treatment rather than ChEI alone should be used in patients with moderate to severe AD to improve global clinical impression (GCI), cognition, behaviour and activities of daily living (ADL). METHODS: A systematic review and meta-analysis of randomized controlled trials based on a literature search in ALOIS, the register of the Cochrane Dementia and Cognitive Improvement Group, was carried out with subsequent guideline development according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system...
June 2015: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
Wen-Jia Jian, Jing Shi, Jin-Zhou Tian, Jing-Nian Ni
OBJECTIVE: Chinese herbal medicine has been extensively used in the treatment of vascular dementia (VaD), but lacked systematic review on its efficacy and safety. So we conducted a systematic review to assess the efficacy and safety of Chinese herbal medicine in treating VaD. METHODS: CNKI, CBM, PubMed, and Wiley Online Library were retrieved for randomized trials (RCTs) on Chinese herbal medicine treating VaD patients. Randomized parallel control trials by taking Chinese herbal medicine as one treatment method and placebos/cholinesterase inhibitors/Memantine hydrochloride as the control were included...
January 2015: Chinese Journal of Integrated Traditional and Western Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"